Saniona (SANION) Life Science Conference 2026 summary

Strategic partnerships and financial position

• Secured major licensing deals with Acadia ($600M) and Jazz ($1B), generating DKK 700M in upfront payments and strengthening financials with DKK 580M in cash at year-end and DKK 820M available for internal development due to upcoming milestones.

• Business model centers on partnerships and out-licensing, enabling self-financed growth and a robust cash position.

• Plans for a sale-leaseback of headquarters to further bolster liquidity.

Pipeline and clinical development

• Internal pipeline targets epilepsy and treatment-resistant depression, addressing significant unmet needs; lead compound SAN2668 for severe pediatric epilepsies shows high efficacy with fewer side effects.

• SAN2465 aims for rapid-onset depression treatment with improved safety over esketamine; SAN2219 targets refractory focal onset seizures with no sedation.

• Acadia is advancing ACP-711 for essential tremor and potentially pain; Jazz will take SAN2355 into phase 1 for epilepsy.

Milestones, studies, and data strategy

• Upcoming milestones include $410M in development and regulatory payments and $1.2B in commercial milestones, with royalties on net sales.

• Phase 1 studies for internal programs to start late 2022 and early 2027, including PET and qEEG biomarker data collection and early proof-of-concept in photosensitive epilepsy patients.

• Near-term inflection points include clinical data readouts and potential research milestones from Boehringer Ingelheim and AstronauTx.